These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1643646)

  • 1. Restricted oncogenicity of BCR/ABL p190 in transgenic mice.
    Voncken JW; Griffiths S; Greaves MF; Pattengale PK; Heisterkamp N; Groffen J
    Cancer Res; 1992 Aug; 52(16):4534-9. PubMed ID: 1643646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.
    Guo JQ; Hirsch-Ginsberg CF; Xian YM; Stass SA; Champlin RE; Giralt SA; McCredie KB; Campbell ML; Arlinghaus RB
    Hematol Pathol; 1993; 7(2):91-106. PubMed ID: 8340287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model mice for BCR/ABL-positive leukemias.
    Honda H; Hirai H
    Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.
    Voncken JW; Kaartinen V; Pattengale PK; Germeraad WT; Groffen J; Heisterkamp N
    Blood; 1995 Dec; 86(12):4603-11. PubMed ID: 8541551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional activation of human LIM-HOX gene hLH-2 in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
    Wu HK; Minden MD
    Biochem Biophys Res Commun; 1997 May; 234(3):742-7. PubMed ID: 9175786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonal characteristics of acute lymphoblastic cells derived from BCR/ABL p190 transgenic mice.
    Griffiths SD; Healy LE; Ford AM; Bennett CA; Voncken JW; Heisterkamp N; Groffen J; Greaves MF
    Oncogene; 1992 Jul; 7(7):1391-9. PubMed ID: 1377812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
    Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
    Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment, characterization, and chromosomal analysis of new leukemic cell lines derived from MT/p210bcr/abl transgenic mice.
    Honda H; Ohno S; Takahashi T; Takatoku M; Yazaki Y; Hirai H
    Exp Hematol; 1998 Mar; 26(3):188-97. PubMed ID: 9502614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
    Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
    Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABL oncogenes directly stimulate two distinct target cells in bone marrow from 5-fluorouracil-treated mice.
    Kelliher MA; Weckstein DJ; Knott AG; Wortis HH; Rosenberg N
    Oncogene; 1993 May; 8(5):1249-56. PubMed ID: 8479746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional activation of human LIM-HOX gene, hLH-2, in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
    Wu HK; Minden MD
    Biochem Biophys Res Commun; 1997 Apr; 233(3):806-12. PubMed ID: 9168938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
    Snyder DS; Wu Y; McMahon R; Yu L; Rossi JJ; Forman SJ
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):179-86. PubMed ID: 9360779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.
    Hemmeryckx B; Reichert A; Watanabe M; Kaartinen V; de Jong R; Pattengale PK; Groffen J; Heisterkamp N
    Oncogene; 2002 May; 21(20):3225-31. PubMed ID: 12082638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
    Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
    Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcr/Abl P190 interaction with Spa-1, a GTPase activating protein for the small GTPase Rap1.
    Yi SJ; Lee HT; Groffen J; Heisterkamp N
    Int J Mol Med; 2008 Oct; 22(4):453-8. PubMed ID: 18813851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Bcr N-terminal oligomerization domain contributes to the full oncogenicity of P190 Bcr/Abl in transgenic mice.
    Heisterkamp N; Voncken JW; Senadheera D; Hemmeryckx B; Gonzalez-Gomez I; Reichert A; Pattengale PK; Groffen J
    Int J Mol Med; 2001 Apr; 7(4):351-7. PubMed ID: 11254872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice.
    Mizuno T; Yamasaki N; Miyazaki K; Tazaki T; Koller R; Oda H; Honda ZI; Ochi M; Wolff L; Honda H
    Oncogene; 2008 May; 27(24):3465-74. PubMed ID: 18193087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
    Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J
    Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.